- Stocks
- Healthcare
- OTC: ENZN

Price (delayed)

$0.2103

Market cap

$15.61M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.02

Enterprise value

-$31.37M

Enzon Pharmaceuticals's net income has surged by 75% QoQ and by 60% YoY

The company's EPS has surged by 50% QoQ and by 33% YoY

The equity has contracted by 30% YoY but it has grown by 24% from the previous quarter

ENZN's revenue has dropped by 96% year-on-year and by 10% since the previous quarter

The gross profit has plunged by 96% YoY and by 10% from the previous quarter

What are the main financial stats of ENZN

Market
Valuations
Earnings

Shares outstanding

74.21M

Market cap

$15.61M

Enterprise value

-$31.37M

Price to earnings (P/E)

N/A

Price to book (P/B)

4.58

Price to sales (P/S)

600.29

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

-1,206.72

Revenue

$26,000

EBIT

-$386,000

EBITDA

-$386,000

Free cash flow

-$659,000

Per share
Balance sheet
Liquidity

EPS

-$0.02

Free cash flow per share

-$0.01

Book value per share

$0.05

Revenue per share

$0

TBVPS

$0.64

Total assets

$47.59M

Total liabilities

$44.18M

Debt

$0

Equity

$3.41M

Working capital

$45.69M

Debt to equity

0

Current ratio

27.89

Quick ratio

27.65

Net debt/EBITDA

121.72

Margins
Efficiency
Dividend

EBITDA margin

-1,484.6%

Gross margin

100%

Net margin

-715.4%

Operating margin

-3,969.2%

Return on assets

-3.1%

Return on equity

-43.3%

Return on invested capital

N/A

Return on capital employed

-0.8%

Return on sales

-1,484.6%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Enzon Pharmaceuticals stock price performed over time

Intraday

-12.01%

1 week

-17.01%

1 month

-22.11%

1 year

-29.9%

YTD

-14.75%

QTD

-14.75%

How have Enzon Pharmaceuticals's revenue and profit performed over time

Revenue

$26,000

Gross profit

$26,000

Operating income

-$1.03M

Net income

-$186,000

Gross margin

100%

Net margin

-715.4%

The operating income has plunged by 120% YoY but it has soared by 58% from the previous quarter

ENZN's revenue has dropped by 96% year-on-year and by 10% since the previous quarter

The gross profit has plunged by 96% YoY and by 10% from the previous quarter

Enzon Pharmaceuticals's net income has surged by 75% QoQ and by 60% YoY

What is Enzon Pharmaceuticals's growth rate over time

What is Enzon Pharmaceuticals stock price valuation

P/E

N/A

P/B

4.58

P/S

600.29

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

-1,206.72

The company's EPS has surged by 50% QoQ and by 33% YoY

The stock's price to book (P/B) is 35% more than its 5-year quarterly average of 3.4 but 28% less than its last 4 quarters average of 6.4

The equity has contracted by 30% YoY but it has grown by 24% from the previous quarter

ENZN's revenue has dropped by 96% year-on-year and by 10% since the previous quarter

The P/S is 5% above the last 4 quarters average of 570.0

How efficient is Enzon Pharmaceuticals business performance

ENZN's return on assets is up by 48% since the previous quarter and by 40% year-on-year

Enzon Pharmaceuticals's return on equity has increased by 43% QoQ but it has decreased by 2.9% YoY

The company's return on sales rose by 43% QoQ

What is ENZN's dividend history

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

Recent dividends

How did Enzon Pharmaceuticals financials performed over time

Enzon Pharmaceuticals's total assets is 8% more than its total liabilities

ENZN's quick ratio has dropped by 77% year-on-year and by 75% since the previous quarter

The current ratio has plunged by 76% YoY and by 75% from the previous quarter

ENZN's debt is 100% smaller than its equity

The equity has contracted by 30% YoY but it has grown by 24% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.